<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112542">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01802866</url>
  </required_header>
  <id_info>
    <org_study_id>4429-202</org_study_id>
    <nct_id>NCT01802866</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride</brief_title>
  <acronym>SEATTLE</acronym>
  <official_title>A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acucela Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Acucela Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if emixustat hydrochloride (ACU-4429) reduces the
      rate of progression of geographic atrophy compared to placebo in subjects with dry
      age-related macular degeneration.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in the total area of the GA lesion(s)</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BCVA score</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AEs, discontinuations due to AEs, or dose modifications; severity and seriousness of AEs</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Geographic Atrophy</condition>
  <arm_group>
    <arm_group_label>ACU-4429 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACU-4429 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACU-4429 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Includes identical tablets with only inactive ingredients (0 mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACU-4429</intervention_name>
    <description>Take orally once daily for 24 months</description>
    <arm_group_label>ACU-4429 2.5 mg</arm_group_label>
    <arm_group_label>ACU-4429 5 mg</arm_group_label>
    <arm_group_label>ACU-4429 10 mg</arm_group_label>
    <other_name>emixustat hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Take orally once daily for 24 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females, age â‰¥55 years.

          2. Clinical diagnosis of GA associated with AMD

          3. Able and willing to provide written informed consent.

          4. Able to reliably administer oral medication by self or with available assistance.

        Exclusion Criteria:

          1. Active CNV or presence of an active ocular disease.

          2. Known serious allergy to the fluorescein sodium for injection in angiography.

          3. Pre-specified laboratory abnormalities at screening.

          4. Treatment with any investigational study drug within 30 days of screening or device
             (within 60 days of screening)

          5. History of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding

          6. Female subjects who are pregnant or lactating.

          7. Female subjects of childbearing potential and male subjects who are not surgically
             sterile who are not willing to practice a medically accepted method of birth control
             from screening through 30 days after completion of the study.

          8. Unstable or poorly controlled medical or ophthalmic conditions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Acucela Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Acucela Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>February 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Geographic atrophy</keyword>
  <keyword>GA</keyword>
  <keyword>Dry AMD</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
